These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9424007)

  • 1. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
    Saunders MI; Hoskin PJ; Pigott K; Powell ME; Goodchild K; Dische S; Denekamp J; Stratford MR; Dennis MF; Rojas AM
    Radiother Oncol; 1997 Nov; 45(2):159-66. PubMed ID: 9424007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.
    Bernier J; Denekamp J; Rojas A; Trovò M; Horiot JC; Hamers H; Antognoni P; Dahl O; Richaud P; Kaanders J; van Glabbeke M; Piérart M
    Radiother Oncol; 1999 Aug; 52(2):149-56. PubMed ID: 10577700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).
    Zackrisson B; Franzén L; Henriksson R; Littbrand B; Stratford M; Dennis M; Rojas AM; Denekamp J
    Acta Oncol; 1994; 33(4):377-81. PubMed ID: 8018369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARCON: experience in 215 patients with advanced head-and-neck cancer.
    Kaanders JH; Pop LA; Marres HA; Bruaset I; van den Hoogen FJ; Merkx MA; van der Kogel AJ
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):769-78. PubMed ID: 11849800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
    Kaanders JH; Pop LA; Marres HA; van der Maazen RW; van der Kogel AJ; van Daal WA
    Radiother Oncol; 1995 Dec; 37(3):190-8. PubMed ID: 8746587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
    Miralbell R; Mornex F; Greiner R; Bolla M; Storme G; Hulshof M; Bernier J; Denekamp J; Rojas AM; Pierart M; van Glabbeke M; Mirimanoff RO
    J Clin Oncol; 1999 Oct; 17(10):3143-9. PubMed ID: 10506611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
    Bernier J; Denekamp J; Rojas A; Minatel E; Horiot J; Hamers H; Antognoni P; Dahl O; Richaud P; van Glabbeke M; Piérart M
    Radiother Oncol; 2000 May; 55(2):111-9. PubMed ID: 10799722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
    Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
    Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
    Bernier J; Stratford MR; Denekamp J; Dennis MF; Bieri S; Hagen F; Kocagöncü O; Bolla M; Rojas A
    Radiother Oncol; 1998 Aug; 48(2):123-33. PubMed ID: 9783883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
    Janssens GO; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Pop LA; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):532-8. PubMed ID: 21300447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
    Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Marres HA; de Bree R; van der Kogel AJ; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
    J Clin Oncol; 2012 May; 30(15):1777-83. PubMed ID: 22508814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
    Hoskin P; Rojas A; Saunders M
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1425-31. PubMed ID: 19036531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARCON: a novel biology-based approach in radiotherapy.
    Kaanders JH; Bussink J; van der Kogel AJ
    Lancet Oncol; 2002 Dec; 3(12):728-37. PubMed ID: 12473514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
    Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
    Hoskin PJ; Rojas AM; Phillips H; Saunders MI
    Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbogen breathing combined with radical radiotherapy in advanced head and neck cancer patients with severe co-morbidities.
    Vees H; Allal AS
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):493-6. PubMed ID: 16909974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
    Horsman MR; Overgaard J
    Radiother Oncol; 2004 Mar; 70(3):301-9. PubMed ID: 15064017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.
    Rojas A; Vojnovic B; Johns H; Joiner MC; Martindale C; Fowler JF; Denekamp J
    Radiother Oncol; 1996 Apr; 39(1):53-64. PubMed ID: 8735494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
    Bussink J; Stratford MR; van der Kogel AJ; Folkes LK; Kaanders JH
    Radiother Oncol; 2002 Jun; 63(3):285-91. PubMed ID: 12142092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
    Janssens GO; van Bockel LW; Doornaert PA; Bijl HP; van den Ende P; de Jong MA; van den Broek GB; Verbist BM; Terhaard CH; Span PN; Kaanders JH
    Eur J Cancer; 2014 Apr; 50(6):1112-9. PubMed ID: 24424106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.